BioCentury | Jan 29, 2021
Management Tracks

KoreaBIO picks Samsung Bioepis’ Ko as presient; plus Adaptive, Omeros, Acadia, ViaCyte, Flexion, Aquestive, GreenLight

...management, will leave the company effective March 2.Nadia Dac joined inflammation, CNS and immune-related diseases play Omeros Corp....
...protect user privacy. BC Staff Acadia Healthcare Co. Inc. GreenLight Biosciences Inc. ViaCyte Inc. Adaptive Biotechnologies Corp. Aquestive Therapeutics Inc. Flexion Therapeutics Inc. Omeros Corp. Samsung...
BioCentury | Jan 21, 2021
Product Development

Jan. 20 Quick Takes: AZ, Daiichi get Enhertu approvals in gastric, breast cancer; plus EdiGene, Merck, Oxford, BMS and Omeros

...significant improvement in overall survival and progression-free survival vs. chemotherapy alone.FDA grants priority review to Omeros’...
...receptor 2PD-1 (PDCD1; CD279) – Programmed cell death 1sGC – Soluble guanylate cyclase Stephen Hansen University of Oxford Omeros Corp. [MERGED]...
BioCentury | Aug 11, 2020
Product Development

Remdesivir heads for FDA review as Gilead continues to build manufacturing pipeline

...Plus data from Omeros, PTC and a call to make mAbs accessible By danielle golovin, staff...
...company announced its NDA submission for the antiviral on a day that saw shares of Omeros...
...$520-per-vial price tag (see “Gilead Disputes Need for March-in Rights”). Narsoplimab helps six recover from ARDS  Omeros Corp....
BioCentury | Dec 6, 2019
Financial News

Financing Roundup: Immunomedics, Ardelyx, Millendo, Omeros, Athenex

...Since market close on Wednesday, Immunomedics, Ardelyx, Millendo and Omeros raised a total of $450 million...
...a share to raise $25 million. The transaction was underwritten by Citigroup and SVB Leerink. Omeros Corp....
...in which the company sold 3.8 million shares at $13.10 a share, a 14% discount. Omeros...
BioCentury | Dec 4, 2019
Clinical News

Omeros’ narsoplimab headed for 1H20 submission on back of readout

...to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy, an Orphan indication with no approved therapies. Omeros Corp....
...who received at least four weeks of treatment survived at least 100 days. Last year Omeros...
...Puerta de Hierro Majadahonda and secretary of the European Society for Blood and Marrow Transplantation. Omeros...
BioCentury | Apr 4, 2019
Company News

Management tracks: Gottlieb's next move, plus Vertex, Centogene and more

...and Clive Bertram as head of corporate development. Yu was VP of clinical development at Omeros Corp....
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

...Inc. raised follow-ons of $195.3 million and $316.2 million, respectively, while The Medicines Co. and Omeros Corp....
...plc (LSE:GSK; NYSE:GSK), London, U.K. Idorsia Ltd., Allschwil, Switzerland Loxo Oncology Inc. (NASDAQ:LOXO), Stamford, Conn. Omeros Corp....
BioCentury | Dec 19, 2018
Distillery Therapeutics

Hematology

...Trasylol for bleeding. Ferring Pharmaceuticals A/S market Lysteda tranexamic acid, a plasmin inhibitor, for menorrhagia. Omeros Corp....
BioCentury | Oct 5, 2018
Clinical News

Omeros' OMS721 underwhelms in Phase II for IgA nephropathy

...a stable, optimized dose of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker. Omeros...
...12-week treatment course had a 67.8% reduction from baseline following an additional course of OMS721. Omeros...
...to enroll about 430 patients and has an estimated primary completion date of May 2020. Omeros...
BioCentury | Oct 2, 2018
Clinical News

Omeros' OMS721 underwhelms in Phase II

...Shares of Omeros Corp. (NASDAQ:OMER) regained some ground Tuesday a day after the stock tumbled on data...
...company lost $10.45 (43%) to $13.96 on Monday, before adding $1.43 (10%) to $15.39 Tuesday. Omeros...
...a stable, optimized dose of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker. Omeros...
Items per page:
1 - 10 of 212
BioCentury | Jan 29, 2021
Management Tracks

KoreaBIO picks Samsung Bioepis’ Ko as presient; plus Adaptive, Omeros, Acadia, ViaCyte, Flexion, Aquestive, GreenLight

...management, will leave the company effective March 2.Nadia Dac joined inflammation, CNS and immune-related diseases play Omeros Corp....
...protect user privacy. BC Staff Acadia Healthcare Co. Inc. GreenLight Biosciences Inc. ViaCyte Inc. Adaptive Biotechnologies Corp. Aquestive Therapeutics Inc. Flexion Therapeutics Inc. Omeros Corp. Samsung...
BioCentury | Jan 21, 2021
Product Development

Jan. 20 Quick Takes: AZ, Daiichi get Enhertu approvals in gastric, breast cancer; plus EdiGene, Merck, Oxford, BMS and Omeros

...significant improvement in overall survival and progression-free survival vs. chemotherapy alone.FDA grants priority review to Omeros’...
...receptor 2PD-1 (PDCD1; CD279) – Programmed cell death 1sGC – Soluble guanylate cyclase Stephen Hansen University of Oxford Omeros Corp. [MERGED]...
BioCentury | Aug 11, 2020
Product Development

Remdesivir heads for FDA review as Gilead continues to build manufacturing pipeline

...Plus data from Omeros, PTC and a call to make mAbs accessible By danielle golovin, staff...
...company announced its NDA submission for the antiviral on a day that saw shares of Omeros...
...$520-per-vial price tag (see “Gilead Disputes Need for March-in Rights”). Narsoplimab helps six recover from ARDS  Omeros Corp....
BioCentury | Dec 6, 2019
Financial News

Financing Roundup: Immunomedics, Ardelyx, Millendo, Omeros, Athenex

...Since market close on Wednesday, Immunomedics, Ardelyx, Millendo and Omeros raised a total of $450 million...
...a share to raise $25 million. The transaction was underwritten by Citigroup and SVB Leerink. Omeros Corp....
...in which the company sold 3.8 million shares at $13.10 a share, a 14% discount. Omeros...
BioCentury | Dec 4, 2019
Clinical News

Omeros’ narsoplimab headed for 1H20 submission on back of readout

...to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy, an Orphan indication with no approved therapies. Omeros Corp....
...who received at least four weeks of treatment survived at least 100 days. Last year Omeros...
...Puerta de Hierro Majadahonda and secretary of the European Society for Blood and Marrow Transplantation. Omeros...
BioCentury | Apr 4, 2019
Company News

Management tracks: Gottlieb's next move, plus Vertex, Centogene and more

...and Clive Bertram as head of corporate development. Yu was VP of clinical development at Omeros Corp....
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

...Inc. raised follow-ons of $195.3 million and $316.2 million, respectively, while The Medicines Co. and Omeros Corp....
...plc (LSE:GSK; NYSE:GSK), London, U.K. Idorsia Ltd., Allschwil, Switzerland Loxo Oncology Inc. (NASDAQ:LOXO), Stamford, Conn. Omeros Corp....
BioCentury | Dec 19, 2018
Distillery Therapeutics

Hematology

...Trasylol for bleeding. Ferring Pharmaceuticals A/S market Lysteda tranexamic acid, a plasmin inhibitor, for menorrhagia. Omeros Corp....
BioCentury | Oct 5, 2018
Clinical News

Omeros' OMS721 underwhelms in Phase II for IgA nephropathy

...a stable, optimized dose of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker. Omeros...
...12-week treatment course had a 67.8% reduction from baseline following an additional course of OMS721. Omeros...
...to enroll about 430 patients and has an estimated primary completion date of May 2020. Omeros...
BioCentury | Oct 2, 2018
Clinical News

Omeros' OMS721 underwhelms in Phase II

...Shares of Omeros Corp. (NASDAQ:OMER) regained some ground Tuesday a day after the stock tumbled on data...
...company lost $10.45 (43%) to $13.96 on Monday, before adding $1.43 (10%) to $15.39 Tuesday. Omeros...
...a stable, optimized dose of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker. Omeros...
Items per page:
1 - 10 of 212